SA
SAB.F Sonic Healthcare Limited
- Market cap
- EUR 6.08B
- P/E
- 17.0x
- P/B
- 1.16x
- ROE
- 7.3%
- Dividend yield
- 5.56%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is SAB.F undervalued?
Graham numberSAB.F trades 6.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sonic Healthcare Limited fundamental analysis
No fundamental analysis for Sonic Healthcare Limited yet.
Sonic Healthcare Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sonic Healthcare Limited
Sonic Healthcare Limited offers medical diagnostic services, and administrative services and facilities to medical practitioners in Australia, the United States, Germany, and internationally. The company provides laboratory medicine/pathology testing services, such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, toxicology, and ancillary functions; and radiology services, including ma…
Full company profileSonic Healthcare Limited financial statements
Sonic Healthcare Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 5.05B | 5.48B | 6.08B | 6.78B | 8.75B | 9.34B | 8.17B | 8.93B | 9.62B | 10.8B |
| Gross Profit | 4.23B | 4.56B | 5.08B | 5.67B | 7.14B | 7.74B | 6.89B | 7.48B | 8.06B | 9.05B |
| Operating Income | 575M | 630M | 700M | 763M | 1.92B | 2.16B | 1.02B | 816M | 905M | 978M |
| EBITDA | 871M | 951M | 1.08B | 1.42B | 2.56B | 2.83B | 1.72B | 1.66B | 1.68B | 1.82B |
| Net Income | 428M | 476M | 550M | 528M | 1.32B | 1.46B | 685M | 511M | 514M | 608M |
| EPS | 1.02 | 1.12 | 1.16 | 1.11 | 2.75 | 3.10 | 1.45 | 1.06 | 1.07 | 1.23 |
| Balance Sheet | ||||||||||
| Total Assets | 7.88B | 8.20B | 9.96B | 12.1B | 11.8B | 12.6B | 13.0B | 14.8B | 16.1B | 16.8B |
| Total Liabilities | 3.95B | 3.92B | 4.47B | 6.46B | 5.26B | 5.12B | 5.09B | 6.75B | 7.58B | 8.29B |
| Shareholders' Equity | 3.83B | 4.18B | 5.41B | 5.57B | 6.38B | 7.27B | 7.74B | 7.92B | 8.32B | 8.34B |
| Cash & Short-term Investments | 438M | 313M | 737M | 1.23B | 900M | 780M | 798M | 645M | 674M | 654M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 736M | 768M | 847M | 1.36B | 2.04B | 2.23B | 1.47B | - | - | - |
| Capital Expenditure | 337M | 226M | 282M | 235M | 274M | 287M | 389M | 580M | 463M | 736M |
| Free Cash Flow | 327M | 440M | 461M | 1.03B | 1.68B | 1.85B | 974M | 492M | 834M | 670M |
| Ratios | ||||||||||
| ROE | 11.2% | 11.4% | 10.2% | 9.5% | 20.6% | 20.1% | 8.9% | 6.5% | 6.2% | 7.3% |
| ROA | 5.4% | 5.8% | 5.5% | 4.4% | 11.2% | 11.6% | 5.3% | 3.4% | 3.2% | 3.6% |
| Net Profit Margin | 8.5% | 8.7% | 9.0% | 7.8% | 15.0% | 15.6% | 8.4% | 5.7% | 5.3% | 5.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sonic Healthcare Limited dividends
- Dividend yield
- 5.56%
- Forward dividend
- 0.67 EUR
- Payout ratio
- 90.6%
- Ex-dividend date
- Sep 2, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | AUD 551M | 1.12 | 90.6% |
| 2025 | AUD 567M | 1.18 | 110.4% |
| 2024 | AUD 559M | 1.16 | 109.4% |
| 2023 | AUD 480M | 1.02 | 70.1% |
| 2022 | AUD 455M | 0.97 | 31.2% |
| 2021 | AUD 416M | 0.87 | 31.6% |
| 2020 | EUR 404M | 0.85 | 76.5% |
| 2019 | EUR 365M | 0.77 | 66.4% |
| 2018 | EUR 234M | 0.55 | 49.1% |
| 2017 | EUR 276M | 0.66 | 64.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Sonic Healthcare Limited
- Insiders 7.99%
- Institutions 48.83%
- Public & others 43.18%
- Shares outstanding 494M
- Free float 460M
Sonic Healthcare Limited company profile
- Company name
- Sonic Healthcare Limited
- Ticker
- SAB.F
- ISIN
- AU000000SHL7
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 47,000
- Fiscal year end
- June
- Address
- Grosvenor Place, Sydney, NSW, Australia, 2000
- Phone
- 61 2 9855 5444
- Website
- sonichealthcare.com
About Sonic Healthcare Limited
Sonic Healthcare Limited offers medical diagnostic services, and administrative services and facilities to medical practitioners in Australia, the United States, Germany, and internationally. The company provides laboratory medicine/pathology testing services, such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, toxicology, and ancillary functions; and radiology services, including magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry (BMD). It also offers primary care medical services comprising general practice clinics, occupational health services, skin cancer clinics, general practice IT solutions, and community-based healthcare services, as well as clinical trials and chronic disease management program services. Sonic Healthcare Limited was incorporated in 1934 and is headquartered in Sydney, Australia.
Sonic Healthcare Limited management
10- Dr. James Pacey NewcombeMD, CEO & Executive Director
- Mr. Christopher David Wilks B.Com., F.A.C.I.D., F.A.I.C.D.Finance Director, CFO & Executive Director · born 1958
- Mr. Evangelos KotsopoulosGroup Chief Operating Officer
- Mr. Matthias HansenChief Digital, Data and Information Officer · born 1964
- Maki TakkenGeneral Counsel
- Graham BealChief People Officer
- Mr. Peter SavageChief Business Officer
- Dr. Stephen FairyChief Medical Officer
- Leisel HickeyChief Procurement Officer
- Jess OnusChief Sustainability Officer